

**Sterne Kessler  
Goldstein Fox**  
ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millionig  
Donald J. Featherstone  
Timothy J. Shea, Jr.  
Michael V. Messinger  
Judith U. Kim

Patrick E. Garrett  
Jeffrey T. Helvey  
Heidi L. Kraus  
Eldora L. Ellison  
Thomas C. Fiala  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Brian J. Del Buono  
Virgil Lee Beaton  
Theodore A. Wood  
Elizabeth J. Haanes  
Joseph S. Ostroff  
Frank R. Cottingham  
Rae Lynn P. Guest  
Daniel A. Klein

Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller  
Jon E. Wright  
LuAnne M. DeSantis  
Ann E. Summerfield  
Aric W. Ledford  
Helene C. Carlson  
Cynthia M. Bouchez  
Timothy A. Doyle  
Gaby L. Longworth  
Lori A. Gordon  
Nicole D. Dretar  
Ted J. Ebersole  
Laura A. Vogel  
Michael J. Mancuso  
Bryan S. Wade  
Aaron L. Schwartz

Shannon A. Carroll\*  
Wesley W. Jones\*  
Matthew E. Kelley\*  
Michelle K. Holoubek\*  
Marsha A. Rose\*

**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Matthew J. Dowd  
Katrina Yujian Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Teresa A. Colella  
Victoria S. Rutherford  
Simon J. Elliott  
Julie A. Heider  
Mita Mukherjee

Scott M. Woodhouse  
Christopher J. Walsh  
Liliana Di Nola-Baron  
Peter A. Socarras  
Jeffrey Mills

**Of Counsel**  
Kenneth C. Bass III  
Marvin C. Guthrie

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

March 21, 2006

**WRITER'S DIRECT NUMBER:**  
(202) 772-8575

**INTERNET ADDRESS:**  
MMUKHERJ@SKGF.COM

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1644**

**Mail Stop Amendment**

Re: U.S. Utility Patent Application  
Application No. 09/350,401; Filed: July 8, 1999  
For: **Inducing Cellular Immune Responses to Hepatitis B Virus Using  
Peptide and Nucleic Acid Compositions**  
Inventors: SETTE *et al.*  
Our Ref: 2473.0060008/PAJ/M-M

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover IDS filing fee;
2. Request for Change of Attorney Docket Number Pleading;
3. Sixth Supplemental Information Disclosure Statement;
4. PTO/SB/08B one (1) page listing cited documents NPL0-NPL8;
5. Copies of cited documents NPL0-NPL8; and
6. A return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
March 21, 2006  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Mita Mukherjee", with a long horizontal flourish extending to the right.

Mita Mukherjee  
Agent for Applicants  
Registration No. 54,325

MM/CLD/tts:awt  
Enclosures

509811v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Sette *et al.*

Application No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune  
Responses to Hepatitis B Virus  
Using Peptide and Nucleic Acid  
Compositions**



Confirmation No.: 8008

Art Unit: 1644

Examiner: Schwadron, R.

Atty. Docket: 2473.0060008/PAJ/M-M

**Request for Change of Attorney Docket Number Pleading**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the attorney docket number for the above-captioned application be changed from "18623-013910" to -- 2473.0060008/PAJ/M-M --. Kindly use this attorney docket number in any future correspondence addressed to the undersigned.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Mita Mukherjee".

Mita Mukherjee  
Agent for Applicants  
Registration No. 54,325

Date: March 21, 2006

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
508820v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sette *et al.*

Appl. No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune  
Responses to Hepatitis B Virus  
Using Peptide and Nucleic Acid  
Compositions**



Confirmation No.: 8008

Art Unit: 1644

Examiner: SCHWADRON, Ronald B.

Atty. Docket: 2473.0060008/PAJ/M-M

**Sixth Supplemental Information Disclosure Statement**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450  
Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

03/22/2006 SZENDIEI 00000112 09350401  
01 FC:1806 180.00 OP

Sette *et al.*  
Appl. No. 09/350,401

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Mita Mukherjee  
Agent for Applicants  
Registration No. 54,325

Date: March 21, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



Approved for use through 07/31/2006. U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
PTO/SB/088 (07-05)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	
SIXTH SUPPLEMENTAL INFORMATION BY APPLICANT	
(Use as many sheets as necessary)	
Sheet	1 of 1
Application Number	09/350,401
§ 371 Date	July 08, 1999
First Named Inventor	Alessandro Sette
Art Unit	1644
Examiner Name	Schwadron, R.
Attorney Docket Number	2473.0060008/PAJ/M-M

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL0	Bertolotti, A. <i>et al.</i> , "Cytotoxic T Lymphocyte Response to a Wild Type Hepatitis B Virus Epitope in Patients Chronically Infected by Variant Viruses Carrying Substitutions within the Epitope," <i>J. Exp. Med.</i> , 180: 933-943 (September 1994).	
	NPL1	Bowie, J.U. <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247: 1306-1310 (March 1990).	
	NPL2	Hosono, S. <i>et al.</i> , "Core Antigen Mutations of Human Hepatitis B Virus in Hepatomas Accumulate in MHC Class II-Restricted T cell Epitopes," <i>Virology</i> , 212: 151-162 (September 1995).	
	NPL3	Kast, W.M. <i>et al.</i> , "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>Journal of Immunology</i> , 152: 3904-12 (April 1994).	
	NPL4	Menne, S. <i>et al.</i> , "Characterization of T-cell response to Woodchuck Hepatitis Virus Core Protein and Protection of Woodchucks from Infection by Immunization with Peptides Containing a T-cell Epitope," <i>Journal of Virology</i> , 71: 65-74 (Jan 1997).	
	NPL5	Piniella, C. <i>et al.</i> , "Functional Importance of Amino Acid Residues Making Up Peptide Antigenic Determinants," <i>Molecular Immunology</i> , 30: 577-585 (April 1993).	
	NPL6	Riftkin, M.C. <i>et al.</i> , "A Single Amino-Acid Change Between the Antigenically Different Extracellular Serine Proteases V2 and B2 from Dichelobacter Nodosus," <i>Gene</i> , 167: 279-283 (December 1995).	
	NPL7	Sarobe, F. <i>et al.</i> , "Enhanced In Vitro Potency and In Vivo Immunogenicity of CTL Epitope from Hepatitis C Virus Core Protein Following Amino Acid Replacement at Secondary HLA-A2.1 Binding Positions," <i>Journal of Clinical Investigation</i> , 102: 1239-48 (September 1998).	
	NPL8	GenPept Accession AAA46769, core protein, NCBI printout, May 4, 1994.	

508728v1

Examiner	Signature	Date	Considered
----------	-----------	------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.